Effect of in vivo administration of ethylmalonic acid on energy metabolism in rat tissues

High concentrations of ethylmalonic acid (EMA) occur in tissues and biological fluids of patients affected by deficiency of short-chain acyl-CoA dehydrogenase activity, as well as in other illnesses characterized by neurological and muscular symptoms. Considering that the pathophysiological mechanis...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Metabolic brain disease 2006-03, Vol.21 (1), p.29-39
Hauptverfasser: FERREIRA, Gustavo Da C, ROTH ANDRE, Karina, SCHUCK, Patricia Fernanda, VIEGAS, Carolina M, TONIN, Anelise, DE MOURA COELHO, Daniella, WYSE, Angela T. S, WANNMACHER, Clovis M. D, VARGAS, Carmen R, WAJNER, Moacir
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 39
container_issue 1
container_start_page 29
container_title Metabolic brain disease
container_volume 21
creator FERREIRA, Gustavo Da C
ROTH ANDRE, Karina
SCHUCK, Patricia Fernanda
VIEGAS, Carolina M
TONIN, Anelise
DE MOURA COELHO, Daniella
WYSE, Angela T. S
WANNMACHER, Clovis M. D
VARGAS, Carmen R
WAJNER, Moacir
description High concentrations of ethylmalonic acid (EMA) occur in tissues and biological fluids of patients affected by deficiency of short-chain acyl-CoA dehydrogenase activity, as well as in other illnesses characterized by neurological and muscular symptoms. Considering that the pathophysiological mechanisms responsible for the clinical manifestations of these diseases are virtually unknown, in the present work we developed a chemical in vivo model of ethylmalonic acidemia in young Wistar rats for neurochemical and behavioral studies through subcutaneous administration of EMA to young rats. The doses of EMA administered subcutaneously varied according to the age of the animals, being injected 3, 4, and 6 micromol g(-1) of body weight in rats of 7, 14, and 21 days, respectively. The concentrations of the acid were measured in blood and brain at regular intervals after a single injection (30-120 min) and reached the highest concentrations (3.0 mM and 0.5 micromol g(-1), approximately 0.5 mM), respectively, after 30 and 60 min of EMA injection. Next, we investigated the effects of acute EMA administration on the activities of complexes I-III, II, II-III, and IV of the respiratory chain in cerebral cortex and skeletal muscle, as well as on the activity of creatine kinase in cerebral cortex, striatum, skeletal muscle, and cardiac muscle of rats of 14 days of life. Control rats were treated with saline in the same volumes. We verified EMA administration did not change these enzymatic activities in all tissues studied. Although transient high concentrations of EMA did not alter important parameters of energy metabolism, it cannot be ruled out that chronic administration of this organic acid would disrupt energy metabolism.
doi_str_mv 10.1007/s11011-006-9004-7
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68077328</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68077328</sourcerecordid><originalsourceid>FETCH-LOGICAL-c317t-6eb842c1feb400116f1316e475ae2abc23af30c4069a7d61cb054a7fd5675c603</originalsourceid><addsrcrecordid>eNqFkU1LxDAURYMoOo7-ADdSBN1V32vSpFmK-AUDbnThKqRpopG20aQjzL83wwwIblwFknNvuBxCThAuEUBcJURALAF4KQFYKXbIDGtBS0F5vUtm0DR1KZiEA3KY0gcA0BrlPjlALgRlvJmR11vnrJmK4Ao_Ft_-OxS6G_zo0xT15MO4frHT-6ofdB9GbwptfFfkezva-LYqBjvpNvQ-DeuCnCkmn9LSpiOy53Sf7PH2nJOXu9vnm4dy8XT_eHO9KA1FMZXctg2rDDrbMshruEOK3DJRa1vp1lRUOwqGAZdadBxNCzXTwnU1F7XhQOfkYtP7GcNX_ndSg0_G9r0ebVgmxRvIY6vmXxAlk4wKlsGzP-BHWMYxj1BVhUhBcswQbiATQ0rROvUZ_aDjSiGotR21saOyHbW2o0TOnG6Ll-1gu9_EVkcGzreATkb3LurR-PTLNdBQiZL-AJ8rlrc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221130961</pqid></control><display><type>article</type><title>Effect of in vivo administration of ethylmalonic acid on energy metabolism in rat tissues</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>FERREIRA, Gustavo Da C ; ROTH ANDRE, Karina ; SCHUCK, Patricia Fernanda ; VIEGAS, Carolina M ; TONIN, Anelise ; DE MOURA COELHO, Daniella ; WYSE, Angela T. S ; WANNMACHER, Clovis M. D ; VARGAS, Carmen R ; WAJNER, Moacir</creator><creatorcontrib>FERREIRA, Gustavo Da C ; ROTH ANDRE, Karina ; SCHUCK, Patricia Fernanda ; VIEGAS, Carolina M ; TONIN, Anelise ; DE MOURA COELHO, Daniella ; WYSE, Angela T. S ; WANNMACHER, Clovis M. D ; VARGAS, Carmen R ; WAJNER, Moacir</creatorcontrib><description>High concentrations of ethylmalonic acid (EMA) occur in tissues and biological fluids of patients affected by deficiency of short-chain acyl-CoA dehydrogenase activity, as well as in other illnesses characterized by neurological and muscular symptoms. Considering that the pathophysiological mechanisms responsible for the clinical manifestations of these diseases are virtually unknown, in the present work we developed a chemical in vivo model of ethylmalonic acidemia in young Wistar rats for neurochemical and behavioral studies through subcutaneous administration of EMA to young rats. The doses of EMA administered subcutaneously varied according to the age of the animals, being injected 3, 4, and 6 micromol g(-1) of body weight in rats of 7, 14, and 21 days, respectively. The concentrations of the acid were measured in blood and brain at regular intervals after a single injection (30-120 min) and reached the highest concentrations (3.0 mM and 0.5 micromol g(-1), approximately 0.5 mM), respectively, after 30 and 60 min of EMA injection. Next, we investigated the effects of acute EMA administration on the activities of complexes I-III, II, II-III, and IV of the respiratory chain in cerebral cortex and skeletal muscle, as well as on the activity of creatine kinase in cerebral cortex, striatum, skeletal muscle, and cardiac muscle of rats of 14 days of life. Control rats were treated with saline in the same volumes. We verified EMA administration did not change these enzymatic activities in all tissues studied. Although transient high concentrations of EMA did not alter important parameters of energy metabolism, it cannot be ruled out that chronic administration of this organic acid would disrupt energy metabolism.</description><identifier>ISSN: 0885-7490</identifier><identifier>EISSN: 1573-7365</identifier><identifier>DOI: 10.1007/s11011-006-9004-7</identifier><identifier>PMID: 16773468</identifier><identifier>CODEN: MBDIEE</identifier><language>eng</language><publisher>New York, NY: Springer</publisher><subject>Acidosis - metabolism ; Age Factors ; Animals ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Butyryl-CoA Dehydrogenase - deficiency ; Cerebral Cortex - drug effects ; Cerebral Cortex - enzymology ; Electron Transport Complex I - metabolism ; Electron Transport Complex II - metabolism ; Electron Transport Complex III - metabolism ; Electron Transport Complex IV - metabolism ; Energy Metabolism - drug effects ; Energy Metabolism - physiology ; Enzyme Activation - drug effects ; Enzyme Activation - physiology ; Female ; Injections, Subcutaneous ; Male ; Malonates - blood ; Malonates - pharmacokinetics ; Medical sciences ; Muscle, Skeletal - drug effects ; Muscle, Skeletal - enzymology ; Myocardium - enzymology ; Neurology ; Neuropharmacology ; Neuroprotective agent ; Pharmacology. Drug treatments ; Pregnancy ; Rats ; Rats, Wistar</subject><ispartof>Metabolic brain disease, 2006-03, Vol.21 (1), p.29-39</ispartof><rights>2006 INIST-CNRS</rights><rights>Springer Science+Business Media, Inc. 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c317t-6eb842c1feb400116f1316e475ae2abc23af30c4069a7d61cb054a7fd5675c603</citedby><cites>FETCH-LOGICAL-c317t-6eb842c1feb400116f1316e475ae2abc23af30c4069a7d61cb054a7fd5675c603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18083919$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16773468$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FERREIRA, Gustavo Da C</creatorcontrib><creatorcontrib>ROTH ANDRE, Karina</creatorcontrib><creatorcontrib>SCHUCK, Patricia Fernanda</creatorcontrib><creatorcontrib>VIEGAS, Carolina M</creatorcontrib><creatorcontrib>TONIN, Anelise</creatorcontrib><creatorcontrib>DE MOURA COELHO, Daniella</creatorcontrib><creatorcontrib>WYSE, Angela T. S</creatorcontrib><creatorcontrib>WANNMACHER, Clovis M. D</creatorcontrib><creatorcontrib>VARGAS, Carmen R</creatorcontrib><creatorcontrib>WAJNER, Moacir</creatorcontrib><title>Effect of in vivo administration of ethylmalonic acid on energy metabolism in rat tissues</title><title>Metabolic brain disease</title><addtitle>Metab Brain Dis</addtitle><description>High concentrations of ethylmalonic acid (EMA) occur in tissues and biological fluids of patients affected by deficiency of short-chain acyl-CoA dehydrogenase activity, as well as in other illnesses characterized by neurological and muscular symptoms. Considering that the pathophysiological mechanisms responsible for the clinical manifestations of these diseases are virtually unknown, in the present work we developed a chemical in vivo model of ethylmalonic acidemia in young Wistar rats for neurochemical and behavioral studies through subcutaneous administration of EMA to young rats. The doses of EMA administered subcutaneously varied according to the age of the animals, being injected 3, 4, and 6 micromol g(-1) of body weight in rats of 7, 14, and 21 days, respectively. The concentrations of the acid were measured in blood and brain at regular intervals after a single injection (30-120 min) and reached the highest concentrations (3.0 mM and 0.5 micromol g(-1), approximately 0.5 mM), respectively, after 30 and 60 min of EMA injection. Next, we investigated the effects of acute EMA administration on the activities of complexes I-III, II, II-III, and IV of the respiratory chain in cerebral cortex and skeletal muscle, as well as on the activity of creatine kinase in cerebral cortex, striatum, skeletal muscle, and cardiac muscle of rats of 14 days of life. Control rats were treated with saline in the same volumes. We verified EMA administration did not change these enzymatic activities in all tissues studied. Although transient high concentrations of EMA did not alter important parameters of energy metabolism, it cannot be ruled out that chronic administration of this organic acid would disrupt energy metabolism.</description><subject>Acidosis - metabolism</subject><subject>Age Factors</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Butyryl-CoA Dehydrogenase - deficiency</subject><subject>Cerebral Cortex - drug effects</subject><subject>Cerebral Cortex - enzymology</subject><subject>Electron Transport Complex I - metabolism</subject><subject>Electron Transport Complex II - metabolism</subject><subject>Electron Transport Complex III - metabolism</subject><subject>Electron Transport Complex IV - metabolism</subject><subject>Energy Metabolism - drug effects</subject><subject>Energy Metabolism - physiology</subject><subject>Enzyme Activation - drug effects</subject><subject>Enzyme Activation - physiology</subject><subject>Female</subject><subject>Injections, Subcutaneous</subject><subject>Male</subject><subject>Malonates - blood</subject><subject>Malonates - pharmacokinetics</subject><subject>Medical sciences</subject><subject>Muscle, Skeletal - drug effects</subject><subject>Muscle, Skeletal - enzymology</subject><subject>Myocardium - enzymology</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Neuroprotective agent</subject><subject>Pharmacology. Drug treatments</subject><subject>Pregnancy</subject><subject>Rats</subject><subject>Rats, Wistar</subject><issn>0885-7490</issn><issn>1573-7365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkU1LxDAURYMoOo7-ADdSBN1V32vSpFmK-AUDbnThKqRpopG20aQjzL83wwwIblwFknNvuBxCThAuEUBcJURALAF4KQFYKXbIDGtBS0F5vUtm0DR1KZiEA3KY0gcA0BrlPjlALgRlvJmR11vnrJmK4Ao_Ft_-OxS6G_zo0xT15MO4frHT-6ofdB9GbwptfFfkezva-LYqBjvpNvQ-DeuCnCkmn9LSpiOy53Sf7PH2nJOXu9vnm4dy8XT_eHO9KA1FMZXctg2rDDrbMshruEOK3DJRa1vp1lRUOwqGAZdadBxNCzXTwnU1F7XhQOfkYtP7GcNX_ndSg0_G9r0ebVgmxRvIY6vmXxAlk4wKlsGzP-BHWMYxj1BVhUhBcswQbiATQ0rROvUZ_aDjSiGotR21saOyHbW2o0TOnG6Ll-1gu9_EVkcGzreATkb3LurR-PTLNdBQiZL-AJ8rlrc</recordid><startdate>20060301</startdate><enddate>20060301</enddate><creator>FERREIRA, Gustavo Da C</creator><creator>ROTH ANDRE, Karina</creator><creator>SCHUCK, Patricia Fernanda</creator><creator>VIEGAS, Carolina M</creator><creator>TONIN, Anelise</creator><creator>DE MOURA COELHO, Daniella</creator><creator>WYSE, Angela T. S</creator><creator>WANNMACHER, Clovis M. D</creator><creator>VARGAS, Carmen R</creator><creator>WAJNER, Moacir</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20060301</creationdate><title>Effect of in vivo administration of ethylmalonic acid on energy metabolism in rat tissues</title><author>FERREIRA, Gustavo Da C ; ROTH ANDRE, Karina ; SCHUCK, Patricia Fernanda ; VIEGAS, Carolina M ; TONIN, Anelise ; DE MOURA COELHO, Daniella ; WYSE, Angela T. S ; WANNMACHER, Clovis M. D ; VARGAS, Carmen R ; WAJNER, Moacir</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c317t-6eb842c1feb400116f1316e475ae2abc23af30c4069a7d61cb054a7fd5675c603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Acidosis - metabolism</topic><topic>Age Factors</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Butyryl-CoA Dehydrogenase - deficiency</topic><topic>Cerebral Cortex - drug effects</topic><topic>Cerebral Cortex - enzymology</topic><topic>Electron Transport Complex I - metabolism</topic><topic>Electron Transport Complex II - metabolism</topic><topic>Electron Transport Complex III - metabolism</topic><topic>Electron Transport Complex IV - metabolism</topic><topic>Energy Metabolism - drug effects</topic><topic>Energy Metabolism - physiology</topic><topic>Enzyme Activation - drug effects</topic><topic>Enzyme Activation - physiology</topic><topic>Female</topic><topic>Injections, Subcutaneous</topic><topic>Male</topic><topic>Malonates - blood</topic><topic>Malonates - pharmacokinetics</topic><topic>Medical sciences</topic><topic>Muscle, Skeletal - drug effects</topic><topic>Muscle, Skeletal - enzymology</topic><topic>Myocardium - enzymology</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Neuroprotective agent</topic><topic>Pharmacology. Drug treatments</topic><topic>Pregnancy</topic><topic>Rats</topic><topic>Rats, Wistar</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FERREIRA, Gustavo Da C</creatorcontrib><creatorcontrib>ROTH ANDRE, Karina</creatorcontrib><creatorcontrib>SCHUCK, Patricia Fernanda</creatorcontrib><creatorcontrib>VIEGAS, Carolina M</creatorcontrib><creatorcontrib>TONIN, Anelise</creatorcontrib><creatorcontrib>DE MOURA COELHO, Daniella</creatorcontrib><creatorcontrib>WYSE, Angela T. S</creatorcontrib><creatorcontrib>WANNMACHER, Clovis M. D</creatorcontrib><creatorcontrib>VARGAS, Carmen R</creatorcontrib><creatorcontrib>WAJNER, Moacir</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Metabolic brain disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FERREIRA, Gustavo Da C</au><au>ROTH ANDRE, Karina</au><au>SCHUCK, Patricia Fernanda</au><au>VIEGAS, Carolina M</au><au>TONIN, Anelise</au><au>DE MOURA COELHO, Daniella</au><au>WYSE, Angela T. S</au><au>WANNMACHER, Clovis M. D</au><au>VARGAS, Carmen R</au><au>WAJNER, Moacir</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of in vivo administration of ethylmalonic acid on energy metabolism in rat tissues</atitle><jtitle>Metabolic brain disease</jtitle><addtitle>Metab Brain Dis</addtitle><date>2006-03-01</date><risdate>2006</risdate><volume>21</volume><issue>1</issue><spage>29</spage><epage>39</epage><pages>29-39</pages><issn>0885-7490</issn><eissn>1573-7365</eissn><coden>MBDIEE</coden><abstract>High concentrations of ethylmalonic acid (EMA) occur in tissues and biological fluids of patients affected by deficiency of short-chain acyl-CoA dehydrogenase activity, as well as in other illnesses characterized by neurological and muscular symptoms. Considering that the pathophysiological mechanisms responsible for the clinical manifestations of these diseases are virtually unknown, in the present work we developed a chemical in vivo model of ethylmalonic acidemia in young Wistar rats for neurochemical and behavioral studies through subcutaneous administration of EMA to young rats. The doses of EMA administered subcutaneously varied according to the age of the animals, being injected 3, 4, and 6 micromol g(-1) of body weight in rats of 7, 14, and 21 days, respectively. The concentrations of the acid were measured in blood and brain at regular intervals after a single injection (30-120 min) and reached the highest concentrations (3.0 mM and 0.5 micromol g(-1), approximately 0.5 mM), respectively, after 30 and 60 min of EMA injection. Next, we investigated the effects of acute EMA administration on the activities of complexes I-III, II, II-III, and IV of the respiratory chain in cerebral cortex and skeletal muscle, as well as on the activity of creatine kinase in cerebral cortex, striatum, skeletal muscle, and cardiac muscle of rats of 14 days of life. Control rats were treated with saline in the same volumes. We verified EMA administration did not change these enzymatic activities in all tissues studied. Although transient high concentrations of EMA did not alter important parameters of energy metabolism, it cannot be ruled out that chronic administration of this organic acid would disrupt energy metabolism.</abstract><cop>New York, NY</cop><pub>Springer</pub><pmid>16773468</pmid><doi>10.1007/s11011-006-9004-7</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0885-7490
ispartof Metabolic brain disease, 2006-03, Vol.21 (1), p.29-39
issn 0885-7490
1573-7365
language eng
recordid cdi_proquest_miscellaneous_68077328
source MEDLINE; SpringerLink Journals
subjects Acidosis - metabolism
Age Factors
Animals
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Butyryl-CoA Dehydrogenase - deficiency
Cerebral Cortex - drug effects
Cerebral Cortex - enzymology
Electron Transport Complex I - metabolism
Electron Transport Complex II - metabolism
Electron Transport Complex III - metabolism
Electron Transport Complex IV - metabolism
Energy Metabolism - drug effects
Energy Metabolism - physiology
Enzyme Activation - drug effects
Enzyme Activation - physiology
Female
Injections, Subcutaneous
Male
Malonates - blood
Malonates - pharmacokinetics
Medical sciences
Muscle, Skeletal - drug effects
Muscle, Skeletal - enzymology
Myocardium - enzymology
Neurology
Neuropharmacology
Neuroprotective agent
Pharmacology. Drug treatments
Pregnancy
Rats
Rats, Wistar
title Effect of in vivo administration of ethylmalonic acid on energy metabolism in rat tissues
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T06%3A45%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20in%20vivo%20administration%20of%20ethylmalonic%20acid%20on%20energy%20metabolism%20in%20rat%20tissues&rft.jtitle=Metabolic%20brain%20disease&rft.au=FERREIRA,%20Gustavo%20Da%20C&rft.date=2006-03-01&rft.volume=21&rft.issue=1&rft.spage=29&rft.epage=39&rft.pages=29-39&rft.issn=0885-7490&rft.eissn=1573-7365&rft.coden=MBDIEE&rft_id=info:doi/10.1007/s11011-006-9004-7&rft_dat=%3Cproquest_cross%3E68077328%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221130961&rft_id=info:pmid/16773468&rfr_iscdi=true